Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2022 | The impact of IGHV mutational status in treatment decisions in CLL

Richard Rosenquist • 7 Oct 2022
ERIC 2022
Chronic Lymphocytic Leukemia Leukemia

Richard Rosenquist, MD, PhD, Karolinska Institute, Stockholm, Sweden, comments on the prognostic value of IGHV mutational status in chronic lymphocytic leukemia (CLL), discussing the impact of these mutations on response to chemoimmunotherapy and targeted therapy. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Richard Rosenquist

1:26
Common genetic tests in CLL & when these tests should be performed
Richard Rosenquist • 7 Oct 2022
1:31
Using genomics to better understand the pathogenesis of CLL & for early disease diagnosis
Richard Rosenquist • 7 Oct 2022
1:38
The importance of TP53 in CLL
Richard Rosenquist • 7 Oct 2022
0:54
Re-testing in CLL: FISH analysis and TP53 screening
Richard Rosenquist • 22 Mar 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals